Check-Cap (NASDAQ:CHEK) vs. Biosig Technologies (NASDAQ:BSGM) Financial Contrast

Check-Cap (NASDAQ:CHEK) and Biosig Technologies (NASDAQ:BSGM) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, analyst recommendations, institutional ownership, profitability and risk.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Check-Cap and Biosig Technologies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Check-Cap	1	0	0	0	1.00
Biosig Technologies	0	0	1	0	3.00

Biosig Technologies has a consensus price target of $10.00, suggesting a potential upside of 57.60%. Given Biosig Technologies’ stronger consensus rating and higher probable upside, analysts clearly believe Biosig Technologies is more favorable than Check-Cap.

Profitability

This table compares Check-Cap and Biosig Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Check-Cap	N/A	N/A	N/A
Biosig Technologies	N/A	-5,336.99%	-90.03%

Institutional & Insider Ownership

1.1% of Check-Cap shares are held by institutional investors. Comparatively, 7.2% of Biosig Technologies shares are held by institutional investors. 0.5% of Check-Cap shares are held by company insiders. Comparatively, 24.8% of Biosig Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

Check-Cap has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500. Comparatively, Biosig Technologies has a beta of 1.82, meaning that its stock price is 82% more volatile than the S&P 500.

Earnings and Valuation

This table compares Check-Cap and Biosig Technologies”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Check-Cap	N/A	N/A	-$25.15 million	($3.00)	-0.68
Biosig Technologies	$13,000.00	15,334.89	-$10.33 million	N/A	N/A

Biosig Technologies has higher revenue and earnings than Check-Cap.

Summary

Biosig Technologies beats Check-Cap on 8 of the 10 factors compared between the two stocks.

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. Check-Cap Ltd. was incorporated in 2004 and is based in Isfiya, Israel.

About Biosig Technologies

BioSig Technologies, Inc., together with its subsidiaries, a medical device company, engages in development and commercialization of advanced digital signal processing technology platform for the treatment of cardiovascular arrhythmias in the United States. It offers PURE EP system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with Mayo Foundation to develop an AI- and machine learning-powered software for PURE EP system. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.